WallStreetZenWallStreetZen

NASDAQ: BPMC
Blueprint Medicines Revenue

OverviewForecastEarningsRevenue
DividendOwnership
Blueprint Medicines revenue was $508.82M for the trailing 12 months ending Dec 31, 2024, with N/A growth year over year. Quarterly revenue for the quarter (Q4 2024) ending on Dec 31, 2024 was $146.4M, up 14.2% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, BPMC annual revenue was $508.8M, with 104% growth year-over-year.

BPMC past revenue growth

How has BPMC's revenue growth performed historically?

Company
104.04%
Industry
437.31%
Market
20.27%
BPMC's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
BPMC's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
BPMC's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

BPMC revenue history

Current Revenue
$508.8M
Current Earnings
-$67.1M
Current Profit Margin
-13.2%

Be the first to know when BPMC announces revenue.

BPMC Revenue History By Year

BPMC Yearly RevenueBPMC RevenueBPMC ChangeBPMC Revenue Growth
2024-12-31$508.82M$259.44M+104.04%
2023-12-31$249.38M$45.34M+22.22%
2022-12-31$204.04M$23.96M+13.30%
2021-12-31$180.08M-$613.66M-77.31%
2020-12-31$793.74M$727.22M+1,093.37%
2019-12-31$66.51M$21.99M+49.39%
2018-12-31$44.52M$23.10M+107.79%
2017-12-31$21.43M-$6.35M-22.85%
2016-12-31$27.77M$16.37M+143.61%
2015-12-31$11.40MN/AN/A
2014-12-31$0.00N/AN/A
2013-12-31$0.00N/AN/A

1 of 1

Blueprint Medicines Revenue FAQ

What was BPMC's revenue last quarter?

On Invalid Date, Blueprint Medicines (NASDAQ: BPMC) reported Q4 2024 revenue of $146.37 million up 103.41% year over year. In the same quarter last year, Blueprint Medicines's revenue was $71.96 million.

What was Blueprint Medicines's revenue in 2024?

Blueprint Medicines's annual revenue for the twelve months ending Dec 31, 2024 was $508.82 million, a 104.04% increase year over year.

How much does Blueprint Medicines make in a day?

Based on Blueprint Medicines annual revenue for the past five years, BPMC makes an average of $1,060,852.05 per day.

What was Blueprint Medicines's annual revenue growth in the past year?

As of Q2 2025, Blueprint Medicines's revenue has grown 104.04% year over year. This is 333.27 percentage points lower than the US Biotechnology industry revenue growth rate of 437.31%. Blueprint Medicines's revenue in the past year totaled $508.82 million.

How much does Blueprint Medicines make in a year?

Blueprint Medicines's revenue by year for the past five years is:
  • Blueprint Medicines's revenue for the twelve months ending Dec 31, 2024 was $508.82 million, a 104.04% increase year over year.
  • Blueprint Medicines's annual revenue for Dec 31, 2023 was $249.38 million, a 22.22% increase from 2022.
  • Blueprint Medicines's annual revenue for 2022 was $204.04 million, a 13.3% increase from 2021.
  • Blueprint Medicines's annual revenue for 2021 was $180.08 million, a 77.31% decrease from 2020.
  • Blueprint Medicines's annual revenue for 2020 was $793.74 million, a 1,093.37% increase from 2019.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.